Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tramiprosate.

Tamsin M Wright1

  • 1Medical Information Department, Prous Science, Barcelona, Spain.

Drugs of Today (Barcelona, Spain : 1998)
|June 28, 2006
PubMed
Summary
This summary is machine-generated.

Tramiprosate, a novel Alzheimer's disease therapy, targets beta-amyloid peptides (Abeta) to potentially halt disease progression. Clinical trials show cognitive benefits and good tolerability, offering hope beyond symptomatic relief for Alzheimer's patients.

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same journal

Monoclonal antibodies for treatment of osteoporosis.

Drugs of today (Barcelona, Spain : 1998)ยท2023
Same journal

Tebentafusp: a novel drug for the treatment of metastatic uveal melanoma.

Drugs of today (Barcelona, Spain : 1998)ยท2023
Same journal

Sugemalimab, a novel PD-L1 inhibitor for treatment of advanced or metastatic non-small cell lung cancer.

Drugs of today (Barcelona, Spain : 1998)ยท2023
Same journal

Secukinumab, ixekizumab, bimekizumab and brodalumab for psoriasis and psoriatic arthritis.

Drugs of today (Barcelona, Spain : 1998)ยท2023
Same journal

Mitapivat for sickle cell disease and thalassemia.

Drugs of today (Barcelona, Spain : 1998)ยท2023
Same journal

Cenegermin for the treatment of dry eye disease.

Drugs of today (Barcelona, Spain : 1998)ยท2023
See all related articles

Area of Science:

  • Neuroscience
  • Pharmacology
  • Drug Development

Background:

  • Current Alzheimer's disease treatments offer only symptomatic relief.
  • Understanding beta-amyloid peptides (Abeta) is key to developing disease-modifying therapies.
  • Tramiprosate represents an advanced antiamyloid therapeutic candidate.

Purpose of the Study:

  • To review the mode of action of tramiprosate.
  • To summarize clinical data on tramiprosate's efficacy and safety in Alzheimer's disease.
  • To explore tramiprosate as a potential disease-modifying therapy for Alzheimer's.

Main Methods:

  • Tramiprosate is a glycosaminoglycan (GAG) mimetic designed to inhibit Abeta.
  • Preclinical studies assessed Abeta levels, fibril formation, and cytoprotective effects.
  • Clinical trials evaluated cognitive function and safety in mild to moderate Alzheimer's disease patients.

Main Results:

  • Preclinical data show reduced Abeta levels and prevention of fibril formation.
  • Phase II clinical trials and extensions suggest cognitive improvement or stabilization.
  • Tramiprosate demonstrated a favorable safety profile with no reported concerns.

Conclusions:

  • Tramiprosate targets early pathogenic events in Alzheimer's disease.
  • Clinical evidence supports tramiprosate's potential efficacy in improving cognitive function.
  • Tramiprosate is a well-tolerated therapeutic option for Alzheimer's disease.